BNP Paribas Financial Markets
BLRX

BNP Paribas Financial Markets’s BioLineRX BLRX Stock Holding History

BNP Paribas Financial Markets’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55K Sell
500
-1,300
-72% -$3.77K ﹤0.01% 5557
2026
Q1 		$4.14K Buy
1,800
+300
+20% +$842 ﹤0.01% 5339
2025
Q4 		$4.16K Buy
+1,500
New +$5.18K ﹤0.01% 5277
2025
Q2 		– Sell
-1,748
Closed -$5.17K – 5461
2025
Q1 		$5.17K Buy
1,748
+314
+22% +$1.26K ﹤0.01% 4848
2024
Q4 		$12.3K Buy
+1,434
New +$21.2K ﹤0.01% 4816

Other funds holding BLRX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
BCV
Banque Cantonale Vaudoise Lausanne, Switzerland $722M AUM 30.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets's BLRX Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its BioLineRX (BLRX) stake by 72% in Q2 2026, selling an estimated $3.77K and leaving 500 shares worth $1.55K. The position accounts for ﹤0.01% of the portfolio, ranked #5557.

BNP Paribas Financial Markets first reported a position in BLRX in Q4 2024 and has held it in 5 quarters since. The position peaked at $12.3K in Q4 2024. 9 funds tracked by Wall St. Rank hold BLRX as of Q2 2026.

  • BNP Paribas Financial Markets held 500 shares of BioLineRX worth $1.55K as of Q2 2026.
  • BNP Paribas Financial Markets sold 1,300 BioLineRX shares in Q2 2026, an estimated $3.77K.
  • BioLineRX made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5557 holding.
  • BNP Paribas Financial Markets first reported a position in BioLineRX in Q4 2024 and has held it in 5 quarters since.
  • BNP Paribas Financial Markets's BioLineRX position peaked at $12.3K in Q4 2024.
  • 9 funds tracked by Wall St. Rank held BioLineRX as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.